Rebamipide

Source: Wikipedia, the free encyclopedia.
Rebamipide
Clinical data
Trade namesMucosta (JP), Rebagen (KR, CN, IN), Rebagit (RU), Rebamax (ID)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets)
ATC code
Identifiers
  • 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
JSmol)
  • Clc1ccc(cc1)C(=O)NC(C(=O)O)CC2=CC(=O)Nc3ccccc32
  • InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26) checkY
  • Key:ALLWOAVDORUJLA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Rebamipide, an

cyclooxygenase-2.[4]

Studies have shown that rebamipide can fight the damaging effects of

GIT mucosa,[5] and more recently, the small intestine, but not for naproxen-induced gastric damage.[6]

Availability

Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China[7] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.[8]

References

  1. PMID 9753220
    .
  2. S2CID 22807270
    .
  3. S2CID 16906464
    .
  4. S2CID 31756608
    .
  5. S2CID 4887031
    .
  6. PMID 27259970
    .
  7. ^ "Rebamipide". Drugs.com.
  8. ^ "Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (in Russian). Russian State Register of Medicines. Retrieved 10 June 2017.
gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rebamipide&oldid=1188103934"